Theratechnologies (NASDAQ:THTX) Trading Up 0.5% - Should You Buy?

Theratechnologies Inc. (NASDAQ:THTX - Get Free Report)'s share price was up 0.5% during trading on Wednesday . The stock traded as high as $2.78 and last traded at $2.76. Approximately 383,922 shares changed hands during mid-day trading, a decline of 52% from the average daily volume of 799,915 shares. The stock had previously closed at $2.74.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on THTX shares. Jones Trading upgraded shares of Theratechnologies from a "hold" rating to a "strong-buy" rating in a report on Friday, April 11th. Research Capitl upgraded shares of Theratechnologies to a "strong-buy" rating in a report on Friday, February 14th.

Theratechnologies Stock Performance

The company has a fifty day simple moving average of $2.03 and a two-hundred day simple moving average of $1.73. The company has a market capitalization of $121.39 million, a price-to-earnings ratio of -26.40 and a beta of 0.56.

Institutional Trading of Theratechnologies

A number of hedge funds have recently added to or reduced their stakes in the business. National Bank of Canada FI boosted its position in shares of Theratechnologies by 2.6% in the first quarter. National Bank of Canada FI now owns 197,068 shares of the company's stock worth $282,000 after acquiring an additional 4,938 shares during the last quarter. Harbour Investments Inc. grew its stake in shares of Theratechnologies by 9.5% during the 1st quarter. Harbour Investments Inc. now owns 96,105 shares of the company's stock valued at $135,000 after buying an additional 8,333 shares during the period. Raymond James Financial Inc. acquired a new stake in shares of Theratechnologies during the 4th quarter worth $27,000. Bank of America Corp DE raised its position in shares of Theratechnologies by 1,416.7% in the 4th quarter. Bank of America Corp DE now owns 16,487 shares of the company's stock worth $30,000 after buying an additional 15,400 shares during the period. Finally, JPMorgan Chase & Co. acquired a new position in Theratechnologies in the fourth quarter valued at $33,000.

Theratechnologies Company Profile

Theratechnologies Inc, a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen.